Patients With Compensated Hepatitis B Virus-Related Cirrhosis and Low-Level Viremia: Treat or Not to Treat?
Journal
The American journal of gastroenterology
ISSN: 1572-0241
Titre abrégé: Am J Gastroenterol
Pays: United States
ID NLM: 0421030
Informations de publication
Date de publication:
01 06 2023
01 06 2023
Historique:
received:
23
01
2023
accepted:
31
01
2023
pmc-release:
01
06
2024
medline:
2
6
2023
pubmed:
21
3
2023
entrez:
20
3
2023
Statut:
ppublish
Résumé
Patients with hepatitis B virus-related cirrhosis and low-level viremia represent a special group that might benefit from treatment because of their higher risk of complications. Evidence for the benefit of treatment in this population is lacking. The current study, which analyzed data of a historical cohort of 627 patients from a single Korean center with hepatitis B virus-related compensated cirrhosis, reported a 2.4-fold increased hepatocellular carcinoma risk among patients with low-level viremia compared with those with undetectable viremia provides indirect evidence in support of treatment for this population. The study underscores the importance of treating patients before the development of cirrhosis and the need for finite duration curative therapy.
Identifiants
pubmed: 36940387
doi: 10.14309/ajg.0000000000002224
pii: 00000434-202306000-00016
pmc: PMC10238665
mid: NIHMS1875575
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Editorial
Research Support, N.I.H., Intramural
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
970-971Subventions
Organisme : Intramural NIH HHS
ID : Z01 DK054517
Pays : United States
Commentaires et corrections
Type : CommentOn
Informations de copyright
Copyright © 2023 by The American College of Gastroenterology.
Références
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018;67(4):1560–99.
Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295(1):65–73.
Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000--summary of a workshop. Gastroenterology 2001;120(7):1828–53.
Chen CJ, Yang HI, Iloeje UH, et al. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009;49(S5):S72–84.
Zacharakis G, Koskinas J, Kotsiou S, et al. The role of serial measurement of serum HBV DNA levels in patients with chronic HBeAg(-) hepatitis B infection: Association with liver disease progression. A prospective cohort study. J Hepatol 2008;49(6):884–91.
Sarin SK, Kumar M, Lau GK, et al. Asian-pacific clinical practice guidelines on the management of hepatitis B: A 2015 update. Hepatol Int 2016;10:1–98.
European Association for the Study of the Liver Electronic address easloffice@easlofficeeu; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67(2):370–98.
Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351(15):1521–31.
Wong GLH, Chan HLY, Mak CWH, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013;58(5):1537–47.
Sinn DH, Lee J, Goo J, et al. Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load. Hepatology 2015;62(3):694–701.
Lee HW, Park SY, Lee YR, et al. Episodic detectable viremia does not affect prognosis in untreated compensated cirrhosis with serum hepatitis B virus DNA <2,000 IU/mL. Am J Gastroenterol 2022;117(2):288–94.
Yang J, Choi W-M, Shim JH, et al. Low level of hepatitis B viremia compared with undetectable viremia increases the risk of hepatocellular carcinoma in patients with untreated compensated cirrhosis. Am J Gastroenterol 2023;118(6):1010–9.
Wong VWS, Janssen HL. Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection? J Hepatol 2015;63(3):722–32.
Ghany MG, King WC, Lisker-Melman M, et al. Comparison of HBV RNA and hepatitis B core related antigen with conventional HBV markers among untreated adults with chronic hepatitis B in North America. Hepatology 2021;74(5):2395–409.
Mak LY, Seto WK, Fung J, et al. New biomarkers of chronic hepatitis B. Gut Liver 2019;13(6):589–95.
Kramvis A, Chang KM, Dandri M, et al. A roadmap for serum biomarkers for hepatitis B virus: Current status and future outlook. Nat Rev Gastroenterol Hepatol 2022;19(11):727–45.
Papatheodoridis GV, Chan HLY, Hansen BE, et al. Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy. J Hepatol 2015;62(4):956–67.
Campbell C, Wang T, McNaughton AL, et al. Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: A systematic review and meta-analysis. J Viral Hepat 2021;28(3):493–507.
Yu MW, Lin CL, Liu CJ, et al. Influence of metabolic risk factors on risk of hepatocellular carcinoma and liver-related death in men with chronic hepatitis B: A large cohort study. Gastroenterology 2017;153(4):1006–17.e5.